Bicon Pharmaceutical was founded in 1997. After restructuring in 2008, Bicon Pharmaceutical became a wholly foreign-owned enterprise wholly owned by Hong Kong Bicon International with its registered capital 937 million RMB.
After strategic reorganization with Furen Pharmaceutical, Bicon is currently a large-scale modern pharmaceutical enterprise group with the integrated businesses covering pharmaceutical raw materials, Chinese patent medicines, chemicals, biological agents, vaccine R&D, production and marketing.
The production base of Bicon Pharmaceutical covers an area of 7.33 hectares and has the largest monomer workshop in Asia up to Good Manufacturing Practice (GMP) standard, with a sterilization space of 32,500 square meters and 15 production lines of tablets, capsules, soft capsules, granules, ointment, oral solution, syrup, large-volume injections, small-volume injections etc. Its annual production capacity is more than 6 billion RMB.
In addition, it has an herbal medicine extraction workshop of 5,000 square meters with an annual extraction capacity of 8,000 tons.
Funding Rounds (2) - $250MUpdate
Xi'an Keji Road E Yang International Building 10F
High-tech Zone, Shaanxi